Tubulointerstitial nephritis during the heterologous phase of nephrotoxic serum nephritis.
This study was designed to characterize the immunopathology of acute tubulointerstitial disease in nephrotoxic serum nephritis in nonsensitized rats. Groups of Lewis rats were studied at 12 time periods ranging from 10 min to 28 days after nephrotoxic serum injection. Nephritic rats developed interstitial nephritis during the acute heterologous phase of renal injury. Coincident with the focal deposition of nephrotoxic antibodies along tubular basement membranes at 24 h, an influx of polymorphonuclear cells and macrophages was evident. The most prominent infiltrate, present between days 3 and 7, was dominated by macrophages with smaller numbers of lymphocytes that were mainly cytotoxic T cells. Dual-labeling studies demonstrated the colocalization of linear tubular basement membrane deposits of the nephrotoxic antibody with focal clusters of interstitial lymphohemopoietic cells. Increased complement deposition was not evident along the tubular basement membranes; moreover, C3 depletion with cobra venom factor failed to attenuate the interstitial inflammation. During the late autologous phase of glomerulonephritis, tubular basement membrane deposits of rat IgG did not appear and the interstitial disease resolved. The results of this study demonstrate that the heterologous phase of nephrotoxic serum nephritis is an antibody-mediated disease directed against the basement membranes not only of the glomeruli but also of some tubules. Antibody deposition is followed by an acute influx of phagocytic cells to both regions of the kidney. These cells may play an important role in the genesis of acute interstitial injury and chronic interstitial fibrosis associated with antiglomerular basement membrane nephritis.
Eddy
A A
AA
Department of Pediatrics, Hospital For Sick Children, University of Toronto, Canada.
D000419:Albuminuria; D000818:Animals; D000906:Antibodies / Q000032:analysis; D003429:Cross Reactions; D005260:Female; D016650:Fluorescein-5-isothiocyanate; D005455:Fluorescent Antibody Technique; D007106:Immune Sera; D007074:Immunoglobulin G; D007382:Intermediate Filaments / Q000648:ultrastructure; D007672:Kidney Cortex / Q000276:immunology / Q000473:pathology*; D008264:Macrophages / Q000276:immunology* / Q000473:pathology; D009395:Nephritis, Interstitial / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D009504:Neutrophils / Q000276:immunology* / Q000473:pathology; D011817:Rabbits / Q000276:immunology; D051381:Rats; D011917:Rats, Inbred Lew; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D014746:Vimentin / Q000032:analysis
D000906:Antibodies; D007106:Immune Sera; D007074:Immunoglobulin G; D014746:Vimentin; D016650:Fluorescein-5-isothiocyanate